Reproductive Health

News on noninvasive prenatal testing, carrier screening, and preimplantation genetic screening.

The company is now seeking commercial partners in Brazil to make the Iona test available in the country.

The goal is to generate clinical outcome and economic data that will make the case to payors to cover NIPT for average-risk pregnancies.

A jury agreed that Ariosa's noninvasive prenatal test infringed several claims in two patents held by Illumina.

Adam Wolfberg argued that while corporate conflicts are widely discussed, physicians also have financial conflicts that can bias them against new technology.

The companies will work together on a new sequencing-based NIPT technology developed by 10x Genomics for the Chinese market.